|Table of Contents|

Research progress on CD44 in digestive system tumors and targeted therapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 06
Page:
1055-1058
Research Field:
Publishing date:

Info

Title:
Research progress on CD44 in digestive system tumors and targeted therapy
Author(s):
WEI Yongjian1; WU Yongna2; ZHANG Lei2; 3; 4; 5; LI Xun1; 2; 3; 4; 5
1.The First School of Clinical Medicine,Lanzhou University,Gansu Lanzhou 730000,China;2.Gansu Key Laboratory of Biotherapy and Regenerative Medicine,Gansu Lanzhou 730000,China;3.Department of General Surgery,the First Hospital of Lanzhou University,Gansu
Keywords:
CD44; digestive system tumor; cancer stem cells; targeted therapy
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2021.06.033
Abstract:
With high incidence and mortality,digestive system malignant tumors affect human health.More effective diagnosis and treatment strategies can improve the prognosis of patients.In recent years,cancer stem cells (CSCs) is considered to be the internal factor of tumor occurrence and development,as well as the important reason of tumor recurrence,metastasis and resistance to radiotherapy and chemotherapy.CD44 is a transmembrane single-chain glycoprotein that can bind to a variety of ligands and has been proved to be a biomarker of CSCs in many kinds of malignant tumors.After selective splicing,there are many subtypes of CD44,such as standard type (CD44s) and variant type (CD44v).CD44 and its subtypes can be used in the diagnosis,treatment and prognosis of tumors,and their role has also been widely studied in the occurrence and development of digestive system malignant tumors.This review highlights the recent advances in the CD44-targeted therapies and the relationship between CD44 and digestive system tumors,in order to provide reference for clinical diagnosis and treatment of digestive system diseases.

References:

［1］BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［2］CHEN W,ZHENG R,BAADE PD,et al. Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［3］BASAKRAN NS. CD44 as a potential diagnostic tumor marker［J］.Saudi Med J,2015,36(3):273-279.
［4］KAROUSOU E,MISRA S,GHATAK S,et al. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer［J］.Matrix Biol,2017,59:3-22.
［5］WATANABE T,OKUMURA T,HIRANO K,et al. Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer［J］.Oncol Lett,2017,13(1):281-288.
［6］XIE JW,CHEN PC,ZHENG CH,et al. Evaluation of the prognostic value and functional roles of CD44v6 in gastric cancer［J］.J Cancer Res Clin Oncol,2015,141(10):1809-1817.
［7］LAU WM,TENG E,CHONG HS,et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells［J］.Cancer Res,2014,74(9):2630-2641.
［8］MASHIMA T,IWASAKI R,KAWATA N,et al. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells［J］.Br J Cancer,2019,121(10):846-856.
［9］HONG I,HONG SW,CHANG YG,et al. Expression of the cancer stem cell markers CD44 and CD133 in colorectal cancer:An immunohistochemical staining analysis［J］.Ann Coloproctol,2015,31(3):84-91.
［10］MOHAMED SY,KAF RM,AHMED MM,et al. The prognostic value of cancer stem cell markers (Notch1,ALDH1,and CD44) in primary colorectal carcinoma［J］.J Gastrointest Cancer,2019,50(4):824-837.
［11］OZAWA M,ICHIKAWA Y,ZHENG YW,et al. Prognostic significance of CD44 variant 2 upregulation in colorectal cancer［J］.Br J Cancer,2014,111(2):365-374.
［12］KATOH S,GOI T,NARUSE T,et al. Cancer stem cell marker in circulating tumor cells:expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness,recurrence and prognosis of human colorectal cancer［J］.Anticancer Res,2015,35(1):239-244.
［13］WANG JL,SU WY,LIN YW,et al. CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer:A meta-analysis［J］.Oncotarget,2017,8(8):12866-12876.
［14］LIU HG,LV L,SHEN H. Intratumoral heterogeneity of CD44v6 in rectal cancer［J］.Clin Transl Oncol,2017,19(4):425-431.
［15］MOKROWIECKA A,VEITS L,FALKEIS C,et al. Expression profiles of cancer stem cell markers:CD133,CD44,Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence［J］.Pathol Res Pract,2017,213(3):205-209.
［16］OKAMOTO K,NINOMIYA I,OHBATAKE Y,et al. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy［J］.Oncol Rep,2016,36(6):3333-3342.
［17］SHEN WD,JI Y,LIU PF,et al. Correlation of E-cadherin and CD44v6 expression with clinical pathology in esophageal carcinoma［J］.Mol Med Rep,2012,5(3):817-821.
［18］YANG H,LIU J,YU H,et al. Expression and association of CD44v6 with prognosis in T2-3N0M0 esophageal squamous cell carcinoma［J］.J Thorac Dis,2014,6(2):91-98.
［19］LI XP,ZHANG XW,ZHENG LZ,et al. Expression of CD44 in pancreatic cancer and its significance［J］.Int J Clin Exp Pathol,2015,8(6):6724-6731.
［20］ZHAO S,CHEN C,CHANG K,et al. CD44 expression level and isoform contributes to pancreatic cancer cell plasticity,invasiveness,and response to therapy［J］.Clin Cancer Res,2016,22(22):5592-5604.
［21］MATZKE-OGI A,JANNASCH K,SHATIRISHVILI M,et al. Inhibition of tumor growth and metastasis in pancreatic cancer models by interference with CD44v6 signaling［J］.Gastroenterology,2016,150(2):513-525.
［22］ZHAO Q,ZHOU H,LIU Q,et al. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma:From patients to patient-derived tumor xenograft models［J］.Oncotarget,2016,7(30):47431-47443.
［23］FU Y,GENG Y,YANG N,et al. CD44v6 expression is associated with a poor prognosis in Chinese hepatocellular carcinoma patients:A meta-analysis［J］.Clin Res Hepatol Gastroenterol,2015,39(6):736-739.
［24］WADA F,KOGA H,AKIBA J,et al. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma:Potential targets by sulfasalazine［J］.Cancer Sci,2018,109(9):2801-2810.
［25］SUN L,FANG Y,WANG X,et al. miR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44［J］.Theranostics,2019,9(26):8409-8425.
［26］SABOOR-MALEKI S,RASSOULI FB,MATIN MM,et al. Auraptene attenuates malignant properties of esophageal stem-like cancer cells［J］.Technol Cancer Res Treat,2017,16(4):519-527.
［27］GAO Y,RUAN B,LIU W,et al. Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition［J］.Oncotarget,2015,6(10):7828-7837.
［28］MIYOSHI S,TSUGAWA H,MATSUZAKI J,et al. inhibiting xCT Improves 5-Fluorouracil resistance of gastric cancer induced by CD44 variant 9 Expression［J］.Anticancer Res,2018,38(11):6163-6170.
［29］THANEE M,LOILOME W,TECHASEN A,et al. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma:A target for cholangiocarcinoma treatment［J］.Cancer Sci,2016,107(7):991-1000.
［30］MISRA S,GHATAK S,VYAS A,et al. Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer［J］.Med Chem Res,2014,23(8):3836-3851.
［31］KIM J,JIANG J,BADAWI M,et al. miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway［J］.Biochem Biophys Res Commun,2017,487(3):709-715.

Memo

Memo:
National Natural Science Foundation of China(No.31570509);国家自然科学基金面上项目（编号：31570509）;甘肃省科技重大专项（编号：1602FKDA001）;兰州市城关区科技局项目（编号：2017SHFZ0014）
Last Update: 1900-01-01